Jones Day represented Cellectis S.A., a French clinical-stage biopharmaceutical developer of innovative cancer treatments using gene editing technologies, in connection with a $175 million public offering of American Depositary Shares on NASDAQ, underwritten by Goldman Sachs & Co. LLC, Citigroup, and Barclays.

Contact: Boris Dolgonos, Renaud Bonnet, Peter E. Devlin